However, the use of a tumor sample for molecular analysis and further mutational analysis of the entire coding sequence of both BRCA1 and BRCA2 may significantly increase the total number of patients who may potentially benefit from targeted therapies with PARP inhibitors. The gene discussed is BRCA1; the disease is neoplasm.